100
Participants
Start Date
May 9, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2030
molecular subtype based treatment
The immunohistochemistry algorithm established by the previous research group was used to determine the molecular subtype, and the corresponding treatment plan was selected according to the subtype. Such as for TCyEM patients, interferon-based immunomodulatory therapy was selected, and TCM-type patients were treated with retinoids.
RECRUITING
Peking University First Hospital, Beijing
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
Peking University Third Hospital, Beijing
Peking University Third Hospital
OTHER
Peking University Cancer Hospital & Institute
OTHER
Peking University First Hospital
OTHER